Scientists find new pathway to trigger growth of new blood vessels in the heart
Washington: Researchers at Washington University School are investigating a signalling molecule called Sonic hedgehog that can overcome problems associated with fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) therapies, which are other methods employed by docs to treat coronary artery disease by promoting growth of new blood vessels in the heart.

Their findings suggest that a drug treatment that turned on or increased hedgehog signals could provide substantial benefit to patients suffering from ischemic heart disease and myocardial infarctions and offer an alternative to invasive procedures like surgery or angioplasty.

About 12 percent of heart patients are not eligible for bypass surgery, which redirects blood around clogged arteries, or for other procedures routinely used to open clogged vessels.

"Our study is the first to identify that hedgehog signaling pathways are operational in the developing and mature heart," says senior author David Ornitz, M.D., Ph.D., the Alumni Endowed Professor of Molecular Biology and Pharmacology.

The hedgehog gene was discovered in fruit flies and named for the spiky appearance of fruit fly embryos with mutations of the gene.

"Hedgehog signaling is a good potential target for growing new vessels in the heart," says first author Kory Lavine, graduate student in molecular biology and pharmacology and student in the Medical Scientist Training Program. "The new vessels would provide an alternative route of blood flow, bypassing clogged vessels and other damage. In effect, hedgehog treatment could grow a natural bypass."
http://www.newkerala.com/news3.php?action=fullnews&id=10137

---

Growth factor triggers growth of new blood vessels in the heart
Jun. 17, 2006



This press release issued by Eurekalert says that the newest concept for treating coronary artery disease is to induce hearts to grow their own new blood vessels to bypass damaged tissue or clogged arteries. Unfortunately, clinical trials of two important blood-vessel growth factors -- fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) -- have not produced stellar results. Now researchers at Washington University School of Medicine in St. Louis have investigated a third signaling molecule -- called Sonic hedgehog -- that could overcome problems associated with FGF2 and VEGF therapy. In a report appearing in the June 15 issue of Genes and Development, the team showed that activating hedgehog signals in adult mouse hearts led to an increase in the density of blood vessels in the heart. Their findings suggest that a drug treatment that turned on or increased hedgehog signals could provide substantial benefit to patients suffering from ischemic heart disease and myocardial infarctions and offer an alternative to invasive procedures like surgery or angioplasty. About 12 percent of heart patients are not eligible for bypass surgery, which redirects blood around clogged arteries, or for other procedures routinely used to open clogged vessels. That means each year in the United States, 100,000 to 200,000 patients could benefit from having another option for improving blood flow in the heart, according to the study's authors. "Our study is the first to identify that hedgehog signaling pathways are operational in the developing and mature heart," says senior author David Ornitz, M.D., Ph.D., the Alumni Endowed Professor of Molecular Biology and Pharmacology. The hedgehog gene was discovered in fruit flies and named for the spiky appearance of fruit fly embryos with mutations of the gene. "Hedgehog signaling is a good potential target for growing new vessels in the heart," says first author Kory Lavine, graduate student in molecular biology and pharmacology and student in the Medical Scientist Training Program. "The new vessels would provide an alternative route of blood flow, bypassing clogged vessels and other damage. In effect, hedgehog treatment could grow a natural bypass." In three large clinical studies, the blood-vessel growth factors FGF2 and VEGF did not result in significant improvement in heart patients who received them. The Washington University scientists demonstrated that hedgehog has an advantage over these growth factors for possible treatment of heart disease because it specifically stimulates blood vessel formation and does so by orchestrating the expression of multiple other growth factors that work together to build new vessels. "Research on development in embryonic mouse hearts has shown that the heart needs multiple factors expressed at the right time, in the right amounts and in the right pattern to grow blood vessels that function properly," Lavine says. "The best way to achieve that is to use a factor that controls and coordinates the activity of multiple blood-vessel growth factors, and we''ve found that hedgehog has this ability." The researchers showed that hedgehog controlled four growth factors: three VEGF proteins (termed VEGF A, B and C) and a protein called angiopoietin 2. They found that hedgehog is sufficient to stimulate normal development of blood vessels in embryonic mouse hearts -- under hedgehog's control, the blood vessels spread out in an orderly fashion from the top of the ventricles of the growing heart to the bottom. The researchers are continuing their studies of hedgehog signaling in the heart to determine its utility in treating heart disease.
http://www.indiadaily.com/breaking_news/73655.asp

---

Public release date: 15-Jun-2006
[ Print Article | E-mail Article | Close Window ]

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Growth factor triggers growth of new blood vessels in the heart
St. Louis, June 15, 2006 -- The newest concept for treating coronary artery disease is to induce hearts to grow their own new blood vessels to bypass damaged tissue or clogged arteries. Unfortunately, clinical trials of two important blood-vessel growth factors -- fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) -- have not produced stellar results.

Now researchers at Washington University School of Medicine in St. Louis have investigated a third signaling molecule -- called Sonic hedgehog -- that could overcome problems associated with FGF2 and VEGF therapy.

In a report appearing in the June 15 issue of Genes and Development, the team showed that activating hedgehog signals in adult mouse hearts led to an increase in the density of blood vessels in the heart.

Their findings suggest that a drug treatment that turned on or increased hedgehog signals could provide substantial benefit to patients suffering from ischemic heart disease and myocardial infarctions and offer an alternative to invasive procedures like surgery or angioplasty.

About 12 percent of heart patients are not eligible for bypass surgery, which redirects blood around clogged arteries, or for other procedures routinely used to open clogged vessels. That means each year in the United States, 100,000 to 200,000 patients could benefit from having another option for improving blood flow in the heart, according to the study's authors.

"Our study is the first to identify that hedgehog signaling pathways are operational in the developing and mature heart," says senior author David Ornitz, M.D., Ph.D., the Alumni Endowed Professor of Molecular Biology and Pharmacology.

The hedgehog gene was discovered in fruit flies and named for the spiky appearance of fruit fly embryos with mutations of the gene.

"Hedgehog signaling is a good potential target for growing new vessels in the heart," says first author Kory Lavine, graduate student in molecular biology and pharmacology and student in the Medical Scientist Training Program. "The new vessels would provide an alternative route of blood flow, bypassing clogged vessels and other damage. In effect, hedgehog treatment could grow a natural bypass."

In three large clinical studies, the blood-vessel growth factors FGF2 and VEGF did not result in significant improvement in heart patients who received them.

The Washington University scientists demonstrated that hedgehog has an advantage over these growth factors for possible treatment of heart disease because it specifically stimulates blood vessel formation and does so by orchestrating the expression of multiple other growth factors that work together to build new vessels.

"Research on development in embryonic mouse hearts has shown that the heart needs multiple factors expressed at the right time, in the right amounts and in the right pattern to grow blood vessels that function properly," Lavine says. "The best way to achieve that is to use a factor that controls and coordinates the activity of multiple blood-vessel growth factors, and we've found that hedgehog has this ability."

The researchers showed that hedgehog controlled four growth factors: three VEGF proteins (termed VEGF A, B and C) and a protein called angiopoietin 2. They found that hedgehog is sufficient to stimulate normal development of blood vessels in embryonic mouse hearts -- under hedgehog's control, the blood vessels spread out in an orderly fashion from the top of the ventricles of the growing heart to the bottom.

The researchers are continuing their studies of hedgehog signaling in the heart to determine its utility in treating heart disease.

###

Lavine KJ, White AC, Park C, Smith CS, Choi K, Long F, Hui C, Ornitz DM. Fibroblast growth factor signals regulate a wave of hedgehog activation that is essential for coronary vascular development. Genes and Development, June 15, 2006.

Funding from the National Institutes of Health, the American Heart Association and the Virginia Friedhofer Charitable Trust supported this research.

Washington University School of Medicine's full-time and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked fourth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.
http://www.eurekalert.org/pub_releases/2006-06/wuso-gft061506.php